| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer |
| Creator | Tarantino et al. |
| Author | P. Tarantino |
| Author | G. Viale |
| Author | M. F. Press |
| Author | X. Hu |
| Author | F. Penault-Llorca |
| Author | A. Bardia |
| Author | A. Batistatou |
| Author | H. J. Burstein |
| Author | L. A. Carey |
| Author | C. Denkert |
| Author | W. Jacot |
| Author | A. K. Koutras |
| Author | A. Lebeau |
| Author | S. Loibl |
| Author | S. Modi |
| Author | M. F. Mosele |
| Author | E. Provenzano |
| Author | G. Pruneri |
| Author | J. S. Reis-Filho |
| Author | F. Rojo |
| Author | R. Salgado |
| Author | P. Schmid |
| Author | S. J. Schnitt |
| Author | S. M. Tolaney |
| Author | D. Trapani |
| Author | A. Vincent-Salomon |
| Author | A. C. Wolff |
| Author | G. Pentheroudakis |
| Author | G. Curigliano |
| Abstract | Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer. The consensus included a multidisciplinary panel of 32 leading experts in the management of breast cancer from nine different countries. The aim of the consensus was to develop statements on topics that are not covered in detail in the current ESMO Clinical Practice Guideline. The main topics identified for discussion were (i) biology of HER2-low breast cancer; (ii) pathologic diagnosis of HER2-low breast cancer; (iii) clinical management of HER2-low metastatic breast cancer; and (iv) clinical trial design for HER2-low breast cancer. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. A review of the relevant scientific literature was conducted in advance. Consensus statements were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This article presents the developed statements, including findings from the expert panel discussions, expert opinion, and a summary of evidence supporting each statement. |
| Publication | Annals of Oncology: Official Journal of the European Society for Medical Oncology |
| Volume | 34 |
| Issue | 8 |
| Pages | 645-659 |
| Date | 2023-08 |
| Journal Abbr | Ann Oncol |
| Language | eng |
| DOI | 10.1016/j.annonc.2023.05.008 |
| ISSN | 1569-8041 |
| Library Catalog | PubMed |
| Extra | PMID: 37269905 |
| Tags | antibody - drug conjugates, breast cancer, Breast Neoplasms, clinic, Consensus, Female, HER2-low, Humans, Medical Oncology |
| Date Added | 2023/10/16 - 15:03:15 |
| Date Modified | 2023/10/16 - 17:27:01 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
